Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Mologen has received approval from the relevant health authorities to carry out a Phase I study using company's MGN1703 cancer drug, which is based on the dSLIM DNA immunomodulator.
Subscribe to our email newsletter
The study will be carried out in cancer patients to test the safety, compatibility and immunological impact of MGN1703. Patients who suffer from the most commonly occurring cancers will be included in the study. It will form the basis of an extensive clinical development program. The company plans to establish MGN1703 as an effective and compatible form of cancer therapy.
The study is to be carried out at the renowned cancer centers of the university clinics of Essen and Cologne and will last approximately six months. The company believes that the study and patient admission can commence in a few weeks, as only the last few formalities required by the authorities still have to be met.
Matthias Schroff, CEO of Mologen, said: “Approval for the MGN1703 study is a great success which rewards our intensive efforts in this field. We now have the chance to demonstrate the great potential for dSLIM as an innovative form of cancer therapy.”